Canada Spends Logo

Explorez notre analyse du budget 2026

Grant: CIHR Fellowship

Direct Payment

$150,000.00

Directed differentiation of human embryonic stem cells towards thymic epithelium for the purpose of inducing immune tolerance to stem cell-derived tissue upon transplantation

EF 2010-11

Résumé
Numerous efforts are currently underway to use stem cells to treat patients suffering from prevalent diseases, including diabetes, Parkinson's disease, and Alzheimer's disease. For example, pancreatic insulin-producing beta cells derived from stem cells could be transplanted to replace lost cells in Type 1 Diabetes as well as in some Type 2 Diabetes patients who have lost the ability to generate sufficient amounts of insulin. However, an important barrier to bringing stem cell therapies to the clinic is the activity of the immune system that is primed to reject the genetically foreign transplanted cells. One strategy that could be used to overcome that problem would be to teach the immune system to accept the foreign stem cell transplants. The objective of the proposed work is thus to generate pancreatic beta cells from human embryonic stem cells (hESCs), a process that is being optimized in Dr. Hebrok's laboratory, but to also generate thymic cells from the same stem cells. The reason for this is that thymus cells are normally involved in excluding cells from the immune system that have the ability to attack cells of their own body. By generating thymic cells from the same hESCs that will form insulin-producing cells, we anticipate that these hESC-derived thymic cells will instruct the immune system not to attack the hESC-derived beta cells. If this strategy proves successful, this work will help improve treatment for many diseases by increasing our ability to put a break on the immune system when transplanting cells or tissue derived from stem cells. This represents an appealing alternative to the current strategies that involve exposing patients to long-term immunosuppression therapy.
Programme
CIHR Fellowship
Bénéficiaire
Emplacement
California, United States of America
Type
Grant
Source
CIHR Funding Decisions Database

Tel que publié

Id
214694
Name
Parent Audrey
Region
California
Country
United States of America
Orgtype
Research Institution
Instname2
Nutrition, Metabolism and Diabetes
Theme2
Biomedical
Prcname2
Fellowships - Post-PhD
Projecttitle
Directed differentiation of human embryonic stem cells towards thymic epithelium for the purpose of inducing immune tolerance to stem cell-derived tissue upon transplantation
Programtype2
Fellowship Programs
Orgnameinp2
Direct Payment
Cihramount2
$150,000
Cihrequipment2
$0
Programname2
CIHR Fellowship
Keyworddelim
Epithelial Thymic Cells; Immune Tolerance; Pancreatic Beta Cells; Stem Cell-Derived Tissue; Stem Cells; Transplantation
Abstract
Numerous efforts are currently underway to use stem cells to treat patients suffering from prevalent diseases, including diabetes, Parkinson's disease, and Alzheimer's disease. For example, pancreatic insulin-producing beta cells derived from stem cells could be transplanted to replace lost cells in Type 1 Diabetes as well as in some Type 2 Diabetes patients who have lost the ability to generate sufficient amounts of insulin. However, an important barrier to bringing stem cell therapies to the clinic is the activity of the immune system that is primed to reject the genetically foreign transplanted cells. One strategy that could be used to overcome that problem would be to teach the immune system to accept the foreign stem cell transplants. The objective of the proposed work is thus to generate pancreatic beta cells from human embryonic stem cells (hESCs), a process that is being optimized in Dr. Hebrok's laboratory, but to also generate thymic cells from the same stem cells. The reason for this is that thymus cells are normally involved in excluding cells from the immune system that have the ability to attack cells of their own body. By generating thymic cells from the same hESCs that will form insulin-producing cells, we anticipate that these hESC-derived thymic cells will instruct the immune system not to attack the hESC-derived beta cells. If this strategy proves successful, this work will help improve treatment for many diseases by increasing our ability to put a break on the immune system when transplanting cells or tissue derived from stem cells. This represents an appealing alternative to the current strategies that involve exposing patients to long-term immunosuppression therapy.
Competitiondate
201010
Approvedterm2
3 yrs 0 mth
Pinamesdelim
Parent, Audrey
Approvedterm
3 ans 0 mois
Cihrcontribution2
~ $150,000~ $0~